Published in Am J Gastroenterol on March 01, 2006
[Trial of device that is not approved or cleared by the U.S. FDA] | NCT01851252
The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol (2009) 1.69
Portal hypertension correlates with splenic stiffness as measured with MR elastography. J Magn Reson Imaging (2011) 1.10
Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management. World J Gastroenterol (2013) 1.03
Portal vein thrombosis in cirrhosis: Controversies and latest developments. World J Gastroenterol (2015) 0.94
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr (2013) 0.93
Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am (2010) 0.92
Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. J Hepatol (2015) 0.90
Beta-blockers in liver cirrhosis. Ann Gastroenterol (2014) 0.90
Hemodynamic effects of the early and long-term administration of propranolol in rats with intrahepatic portal hypertension. Hepatol Int (2008) 0.90
Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond. World J Gastroenterol (2014) 0.89
Effect of propranolol on portal pressure and systemic hemodynamics in patients with liver cirrhosis and portal hypertension: a prospective study. Gut Liver (2007) 0.89
Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World J Gastroenterol (2014) 0.88
Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. World J Hepatol (2015) 0.88
Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension. Clin Mol Hepatol (2014) 0.86
Improving survival in decompensated cirrhosis. Int J Hepatol (2012) 0.86
Primary prophylaxis of variceal hemorrhage in children with portal hypertension: a framework for future research. J Pediatr Gastroenterol Nutr (2011) 0.84
Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis. Can J Gastroenterol (2011) 0.84
Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis. Clin Gastroenterol Hepatol (2010) 0.84
The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82
Hepatic venous pressure gradient: worth another look? Dig Dis Sci (2008) 0.80
Nonselective β-blockers may induce development of portal vein thrombosis in cirrhosis. World J Gastroenterol (2014) 0.78
Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol (2013) 0.77
An assessment of surgery for portal hypertensive patients performed at a single community hospital. Surg Today (2010) 0.77
Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis? Clin Mol Hepatol (2012) 0.76
The low incidence of bacterial infections could be a protective factor against variceal bleeding per se in hemodynamic responders to propranolol. Am J Gastroenterol (2006) 0.76
Impact of splenic circulation: non-invasive microbubble-based assessment of portal hemodynamics. Eur Radiol (2014) 0.76
Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension. ISRN Hepatol (2013) 0.75
Use of ß-blocker therapy to prevent primary bleeding of esophageal varices. J Am Acad Nurse Pract (2010) 0.75
Determination of correlation of Adjusted Blood Requirement Index with outcome in patients presenting with acute variceal bleeding. World J Gastroenterol (2009) 0.75
Assessment of risk of complications in cirrhosis using portal thallium scans. World J Gastroenterol (2014) 0.75
Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Am J Gastroenterol (2016) 0.75
Pediatric gastrointestinal bleeding: Perspectives from the Italian Society of Pediatric Gastroenterology. World J Gastroenterol (2017) 0.75
Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window. World J Gastroenterol (2015) 0.75
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med (2010) 5.37
Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol (2012) 4.62
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology (2012) 3.86
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology (2013) 3.31
Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology (2010) 2.82
Multiple emergences of genetically diverse amphibian-infecting chytrids include a globalized hypervirulent recombinant lineage. Proc Natl Acad Sci U S A (2011) 2.78
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology (2006) 2.72
Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology (2006) 2.39
Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology (2010) 2.39
Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest (2011) 2.36
A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol (2008) 2.35
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology (2009) 2.33
Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med (2009) 2.26
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology (2006) 2.03
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (2013) 1.93
Good long-term outcome of Budd-Chiari syndrome with a step-wise management. Hepatology (2013) 1.89
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol (2005) 1.87
Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut (2011) 1.87
The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology (2007) 1.86
An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl (2007) 1.83
Current management of portal hypertension. J Hepatol (2003) 1.81
Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology (2009) 1.76
Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology (2004) 1.71
How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers. Gastroenterology (2007) 1.70
The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol (2009) 1.69
Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology (2008) 1.66
Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut (2011) 1.66
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology (2003) 1.64
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology (2011) 1.63
Mitigating amphibian disease: strategies to maintain wild populations and control chytridiomycosis. Front Zool (2011) 1.62
Effects of splenic artery occlusion on portal pressure in patients with cirrhosis and portal hypertension. Liver Transpl (2006) 1.60
Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol (2007) 1.60
Factors driving pathogenicity vs. prevalence of amphibian panzootic chytridiomycosis in Iberia. Ecol Lett (2010) 1.60
Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol (2009) 1.57
An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology (2009) 1.54
Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study. Hepatology (2010) 1.53
Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. J Hepatol (2010) 1.53
Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. J Hepatol (2007) 1.51
Portal hypertension and its complications. Gastroenterology (2008) 1.50
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology (2009) 1.49
Proteomic and phenotypic profiling of the amphibian pathogen Batrachochytrium dendrobatidis shows that genotype is linked to virulence. Mol Ecol (2009) 1.49
Portal hypertension in children: expert pediatric opinion on the report of the Baveno v Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. Pediatr Transplant (2012) 1.49
The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol (2012) 1.48
Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int (2013) 1.46
The management of portal hypertension: rational basis, available treatments and future options. J Hepatol (2008) 1.43
Chytrid fungus in Europe. Emerg Infect Dis (2005) 1.43
Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. Hepatology (2014) 1.43
Use of noninvasive markers of portal hypertension and timing of screening endoscopy for gastroesophageal varices in patients with chronic liver disease. Hepatology (2013) 1.43
Non invasive evaluation of portal hypertension using transient elastography. J Hepatol (2011) 1.42
Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. Hepatology (2006) 1.42
Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology (2006) 1.41
Anticoagulation in cirrhosis: ready … set … wait! Hepatology (2013) 1.41
Portal hypertension and variceal bleeding--unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology (2008) 1.40
Developments and controversies in the management of oesophageal and gastric varices. Gut (2010) 1.40
A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients. Am J Gastroenterol (2010) 1.38
Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol (2010) 1.37
Invasive pathogens threaten species recovery programs. Curr Biol (2008) 1.37
Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology (2002) 1.30
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology (2004) 1.30
Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis (2006) 1.29
Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol (2004) 1.28
Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol (2012) 1.23
Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology (2013) 1.23
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology (2007) 1.23
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology (2008) 1.21
Endoscopic band ligation in the treatment of portal hypertension. Nat Clin Pract Gastroenterol Hepatol (2005) 1.20